A new device for the injection of tralokinumab is one step closer to approval in European Union member states.
The Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended the approval of a pre-filled 2 ml pen that contains a 300 mg dose of tralokinumab, the
manufacturer, Leo Pharma, announced in a June 23Tralokinumab, an interleukin-13 antagonist, is currently available in a 1 ml pre-filled syringe . It is currently approved for treating moderate to severe
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
New York officials announce new e-bike safety measures after deadly Chinatown fireNew York officials announced new e-bike safety measures after a fire at an e-bike repair shop killed four people last week in Chinatown.
Consulte Mais informação »
New York congestion pricing to get federal green light, New Jersey lawmakers sayHistorically, New York and New Jersey are codependent states that don’t hesitate to fight over things like land, water rights or authority.
Consulte Mais informação »
New Lenox carjacking: 2 Chicago residents arrested, new details releasedA Chicago man and teenager have been arrested in connection to a violent carjacking in New Lenox last week.
Consulte Mais informação »
Surging Giants look to continue charge in finale vs. D-backsThe Giants will get an opportunity to move within a half-game of the National League West-leading Arizona Diamondbacks on Sunday when the clubs complete a three-game series in San Francisco.
Consulte Mais informação »
Blinken backs Biden after he called China's Xi a dictator“The president always speaks candidly, he speaks directly. He speaks clearly, and he speaks for all of us,” he said.
Consulte Mais informação »
Why linebackers and running backs are participating in the 7-on-7 state tournamentCOLLEGE STATION — 7-on-7 football is built for quarterbacks and wide receivers. The two positions are set up to succeed, given the rules and restrictions...
Consulte Mais informação »